Yuan-Ming Yeh1, Kuo-An Wu2,3, Chia-Yu Yang4,5,6, Shiao-Wen Li6, Chia-Yin Chin6, Chia-Wei Hsu6,7, Chi-Ching Lee8. 1. Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan. 2. Department of Internal Medicine, Taoyuan Armed Forces General Hospital, No. 168, Zhongxing Rd., Longtan District, Taoyuan, 32551, Taiwan (R.O.C.). wu5830@ms26.hinet.net. 3. School of Medicine, Fu Jen Catholic University, New Taipei City, 24205, Taiwan. wu5830@ms26.hinet.net. 4. Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Taoyuan, Taiwan. 5. Department of Otolaryngology-Head and Neck Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 6. Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan. 7. Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan. 8. Department and Graduate Institute of Computer Science and Information Engineering, Chang Gung University, Taoyuan, Taiwan.
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive, life-threatening lung disease with increasing prevalence and incidence worldwide. Increasing evidence suggests that lung microbiomes might play a physiological role in acute exacerbations of COPD. The objective of this study was to characterize the association of the microbiota and exacerbation risk or airflow limitation in stable COPD patients. METHODS: The sputum microbiota from 78 COPD outpatients during periods of clinical stability was investigated using 16S rRNA V3-V4 amplicon sequencing. The microbiome profiles were compared between patients with different risks of exacerbation, i.e., the low risk exacerbator (LRE) or high risk exacerbator (HRE) groups, and with different airflow limitation severity, i.e., mild to moderate (FEV1 ≥ 50; PFT I) or severe to very severe (FEV1 < 50; PFT II). RESULTS: The bacterial diversity (Chao1 and observed OTUs) was significantly decreased in the HRE group compared to that in the LRE group. The top 3 dominant phyla in sputum were Firmicutes, Actinobacteria, and Proteobacteria, which were similar in the HRE and LRE groups. At the genus level, compared to that in the LRE group (41.24%), the proportion of Streptococcus was slightly decreased in the HRE group (28.68%) (p = 0.007). However, the bacterial diversity and the proportion of dominant bacteria at the phylum and genus levels were similar between the PFT I and PFT II groups. Furthermore, the relative abundances of Gemella morbillorum, Prevotella histicola, and Streptococcus gordonii were decreased in the HRE group compared to those in the LRE group according to linear discriminant analysis effect size (LEfSe). Microbiome network analysis suggested altered bacterial cooperative regulation in different exacerbation phenotypes. The proportions of Proteobacteria and Neisseria were negatively correlated with the FEV1/FVC value. According to functional prediction of sputum bacterial communities through Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) analysis, genes involved in lipopolysaccharide biosynthesis and energy metabolism were enriched in the HRE group. CONCLUSION: The present study revealed that the sputum microbiome changed in COPD patients with different risks of exacerbation. Additionally, the bacterial cooperative networks were altered in the HRE patients and may contribute to disease exacerbation. Our results provide evidence that sputum microbiome community dysbiosis is associated with different COPD phenotypes, and we hope that by understanding the lung microbiome, a potentially modifiable clinical factor, further targets for improved COPD therapies during the clinically stable state may be elucidated.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is a progressive, life-threatening lung disease with increasing prevalence and incidence worldwide. Increasing evidence suggests that lung microbiomes might play a physiological role in acute exacerbations of COPD. The objective of this study was to characterize the association of the microbiota and exacerbation risk or airflow limitation in stable COPDpatients. METHODS: The sputum microbiota from 78 COPD outpatients during periods of clinical stability was investigated using 16S rRNA V3-V4 amplicon sequencing. The microbiome profiles were compared between patients with different risks of exacerbation, i.e., the low risk exacerbator (LRE) or high risk exacerbator (HRE) groups, and with different airflow limitation severity, i.e., mild to moderate (FEV1 ≥ 50; PFT I) or severe to very severe (FEV1 < 50; PFT II). RESULTS: The bacterial diversity (Chao1 and observed OTUs) was significantly decreased in the HRE group compared to that in the LRE group. The top 3 dominant phyla in sputum were Firmicutes, Actinobacteria, and Proteobacteria, which were similar in the HRE and LRE groups. At the genus level, compared to that in the LRE group (41.24%), the proportion of Streptococcus was slightly decreased in the HRE group (28.68%) (p = 0.007). However, the bacterial diversity and the proportion of dominant bacteria at the phylum and genus levels were similar between the PFT I and PFT II groups. Furthermore, the relative abundances of Gemella morbillorum, Prevotella histicola, and Streptococcus gordonii were decreased in the HRE group compared to those in the LRE group according to linear discriminant analysis effect size (LEfSe). Microbiome network analysis suggested altered bacterial cooperative regulation in different exacerbation phenotypes. The proportions of Proteobacteria and Neisseria were negatively correlated with the FEV1/FVC value. According to functional prediction of sputum bacterial communities through Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) analysis, genes involved in lipopolysaccharide biosynthesis and energy metabolism were enriched in the HRE group. CONCLUSION: The present study revealed that the sputum microbiome changed in COPDpatients with different risks of exacerbation. Additionally, the bacterial cooperative networks were altered in the HRE patients and may contribute to disease exacerbation. Our results provide evidence that sputum microbiome community dysbiosis is associated with different COPD phenotypes, and we hope that by understanding the lung microbiome, a potentially modifiable clinical factor, further targets for improved COPD therapies during the clinically stable state may be elucidated.
Authors: Raminder Aul; Jane Armstrong; Annelyse Duvoix; David Lomas; Brian Hayes; Bruce E Miller; Chris Jagger; Dave Singh Journal: Br J Clin Pharmacol Date: 2012-12 Impact factor: 4.335
Authors: Alvar Agustí; Stephen Rennard; Lisa D Edwards; William MacNee; Emiel Wouters; Bruce Miller; Ruth Tal-Singer; Hana Mullerova; Bartolomé Celli Journal: Eur Respir J Date: 2015-07 Impact factor: 16.671
Authors: Tom M A Wilkinson; Irem S Patel; Mark Wilks; Gavin C Donaldson; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2003-01-24 Impact factor: 21.405
Authors: Sam Lim; David Chi-Leung Lam; Abdul Razak Muttalif; Faisal Yunus; Somkiat Wongtim; Le Thi Tuyet Lan; Vikram Shetty; Romeo Chu; Jinping Zheng; Diahn-Warng Perng; Teresita de Guia Journal: Asia Pac Fam Med Date: 2015-04-23
Authors: Alexa A Pragman; Tianmeng Lyu; Joshua A Baller; Trevor J Gould; Rosemary F Kelly; Cavan S Reilly; Richard E Isaacson; Chris H Wendt Journal: Microbiome Date: 2018-01-09 Impact factor: 14.650